NAYA
vs
S&P 500
NAYA
S&P 500
Over the past 12 months, NAYA has underperformed S&P 500, delivering a return of -63% compared to the S&P 500's +19% growth.
Stocks Performance
NAYA vs S&P 500
Performance Gap
NAYA vs S&P 500
Performance By Year
NAYA vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
NAYA Biosciences Inc
Glance View
INVO BioScience, Inc. is a fertility company. The company is headquartered in Sarasota, Florida and currently employs 25 full-time employees. The company went IPO on 2008-11-11. The Company’s initial pipeline includes two novel Flex-NK Bispecific Antibodies. NY-303: its GPC3-targeted FLEX-NK Bispecific Antibody for Hepatocellular Carcinoma (HCC). NY-338: its CD38-targeted FLEX-NK Bispecific Antibody for Multiple Myeloma (MM) & Autoimmune Diseases. Its lead GPC3-targeting FLEX-NK bispecific antibody is entering Phase I/II clinical trials and positioned as a monotherapy option to address the unmet needs of the of hepatocellular carcinoma (HCC) patients not responding to standard of care with checkpoint inhibitors. INVOcell is its novel, FDA-cleared and CE-marked intravaginal culture (IVC) device. The company offers a viable alternative to vitro fertilization (IVF) that uses the female body for fertilization and incubation, keeping women at the center of the reproductive process.